Negotiations database

Indication:

Primary hyperlipidemia and cardiovascular disease

Indication:

For the treatment of adults and adolescents 12 years and older with severe alopecia areata

Indication:

In combination with trastuzumab and chemotherapy for the neoadjuvant treatment of adult patients with early-stage HER2-positive breast cancer

Indication:

​As an adjunct to diet to reduce triglyceride levels for adult patients with genetically confirmed or clinically diagnosed familial chylomicronemia syndrome (FCS) for whom standard triglyceride lowering therapies have been inadequate.

Indication:

For the acute treatment of migraine, with or without aura, in adults

Indication:

Chronic hand eczema

Indication:

Braftovi, in combination with cetuximab and mFOLFOX6, for the treatment of patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by a validated test

Indication:

For the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody, and have demonstrated disease progression on or after the last therapy.

Indication:

for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody, and have demonstrated disease progression on or after the last therapy

Indication:

As monotherapy for the treatment of adult patients with relapsed or refractory follicular lymphoma (Grades 1 – 3a) who have received at least two prior lines of systemic therapy.